A Study of Crenolanib With Fludarabine and Cytarabine in Pediatric Patients With Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia

NCT03324243 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Withdrawn: Study halted prior to enrollment of first participant

Conditions

Relapsed/Refractory FLT3-mutated AML

Interventions

DRUG: Crenolanib
DRUG: Fludarabine
DRUG: Cytarabine

Sponsor

Arog Pharmaceuticals, Inc.